CASCADE THERAPEUTICS, INC.

Biotech · Private

Novel small-molecule therapeutic compounds derived from natural products for treating P. falciparum malaria, including artemisinin-resistant strains

Grants
$707K
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Evaluation of Natural Products and Derivatives as Antimalarial Agents$225,000
Federal grantDepartment of Health and Human Services · Phase I · Development of Natural Product Derivatives as Antiprotozoal Agents$225,000
Federal grantDepartment of Health and Human Services · Phase I · Discovery of Small Molecules as Antimalarial Agents$256,500
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3044Panorama Research Incorporated——
3045E&E BIOCLUB LLC——
3046VIRONIKA LLC——
3047CASCADE THERAPEUTICS, INC.——
3048BACCHUS THERAPEUTICS INC——
3049INFINITESIMAL, LLC——
3050PROTEIN POTENTIAL LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.